Press Release: Xolair : Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR (omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC today announced the completion of patient enrollment for its Phase III clinical trial of ADL018, a biosimilar candidate to XOLAIR®. This pivotal study aims to compare the efficacy, safety, tolerability, and immunogenicity of ADL018 with XOLAIR® in patients with chronic idiopathic/spontaneous urticaria (CSU) who remain symptomatic despite taking H1 antagonists. This clinical trial enrolled total 600 patients across multiple sites globall